AnaptysBio’s (ANAB) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of AnaptysBio (NASDAQ:ANAB) in a research note published on Monday,Benzinga reports. The brokerage currently has a $66.00 price objective on the biotechnology company’s stock.

ANAB has been the topic of several other reports. UBS Group upped their price objective on shares of AnaptysBio from $70.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Wall Street Zen downgraded shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Guggenheim reissued a “buy” rating on shares of AnaptysBio in a research report on Thursday, December 18th. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Stifel Nicolaus raised their price objective on shares of AnaptysBio from $56.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.10.

AnaptysBio Price Performance

Shares of ANAB opened at $56.73 on Monday. The firm has a market cap of $1.63 billion, a PE ratio of -109.09 and a beta of 0.40. The stock’s fifty day moving average price is $55.88 and its two-hundred day moving average price is $44.33. AnaptysBio has a 1 year low of $15.40 and a 1 year high of $68.39.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. Sell-side analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio announced that its Board of Directors has initiated a share repurchase program on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 5,352,316.2% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company’s management believes its stock is undervalued.

Insider Activity at AnaptysBio

In other AnaptysBio news, insider Paul F. Lizzul sold 4,219 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $43.26, for a total value of $182,513.94. Following the completion of the transaction, the insider directly owned 33,303 shares of the company’s stock, valued at $1,440,687.78. This trade represents a 11.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Eric J. Loumeau sold 10,000 shares of the business’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total transaction of $540,000.00. Following the transaction, the insider owned 12,835 shares of the company’s stock, valued at $693,090. This trade represents a 43.79% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 110,193 shares of company stock valued at $5,333,138 in the last quarter. 33.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On AnaptysBio

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC boosted its stake in AnaptysBio by 5,864.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 821 shares during the period. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 473 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of AnaptysBio by 950.0% in the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in shares of AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 1,377 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its position in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 2,326 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.